150 likes | 291 Views
Thrombolysis for stroke & remaining uncertainties after ECASS3; clues from the type of patients recruited in IST-3. Peter Sandercock On behalf of the IST-3 Collaborative Group UK Stroke Forum Glasgow, 3 rd December 2009. Uncertainties* about thrombolysis in acute ischaemic stroke.
E N D
Thrombolysis for stroke &remaining uncertainties after ECASS3; clues from the type of patients recruited in IST-3 Peter Sandercock On behalf of the IST-3 Collaborative Group UK Stroke Forum Glasgow, 3rd December 2009
Uncertainties* about thrombolysis in acute ischaemic stroke • Is the upper age limit of 80 years justified? • What key features identify patients most likely to benefit? • Severity (e.g. NIHSS)? • Stroke syndrome (LACI, TACI, POCI)? • Radiological (e.g. Hyperdense artery, WML)? • What is the latest time for net benefit? • Baseline features of IST-3 patients could indicate what participating clinicians are most uncertain about *Wardlaw et al BMJ 2009 339; b4584
IST-3 trial: eligibility If patient fits main eligibility criteria, Clinician/patient/family discuss. If: • ClearINDICATION FORrt-PA TREAT (i.e. meets terms of current licence and patient agrees) • Clear CONTRAINDICATION TOrt-PA DON’T TREAT • rt-PA ‘PROMISING BUT UNPROVEN’ RANDOMISE
IST - 3 Methods & data • Randomised, open, blinded outcomes study of i.v. rt-PA vs control, • Primary outcome: the proportion of patients alive and independent at six months • Randomisation by telephone or via web • Imaging: structural CT or MR + perfusion/angio data if available -> expert central review • Target 3100 patients by end June 2011 • Analysis of baseline data on the 1787 patients recruited by 6th September 2009
Age Over 800 patients aged > 80 years
OCSP clinical syndrome POCI LACI TACI PACI
Time onset to randomisation 42% 33% 25%
Trends in time onset to randomisation Median (hrs) 4.0 4.0 3.9 3.8 4.0
Number of patients recruited per quarter year in each age and time stratum Age time(h)
Summary • The type of patients recruited reflects the ‘grey area of uncertainty’ of the participating clinicians • Broad entry criteria enable IST-3 to add evidence on effects of rt-PA among • Older patients • Mild, moderate and severe stroke • Patients treated up to 6 hours • Clinical subtypes (LACI,TACI, PACI, POCI) • IST-3 will help determine role of brain imaging • Structural CT, MR • (Vascular CT/MR Perfusion, angiography) in a subset
Acknowledgements: The patients, the 116 participating hospitals, the Data Monitoring Committee, the MRC Steering Committee, the Expert Image Reading Panel, the International Advisory Board, the Event adjudication panel, and:
IST-3. A large randomised trial: can a wider variety of patients be treated with iv therapy? Target: 3100 patients by mid 2011